Marshall Wace, LLP Syros Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $56,504 - $99,088	-81,891 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.02 - $3.8 $83,528 - $311,185	81,891 New	81,891 $97,000
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $598,050 - $854,881	-183,451 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.08 - $5.66 $460,852 - $639,319	-112,954 Reduced 38.11%	183,451 $820,000
Q2 2021 Aug 13, 2021	BUY	$5.01 - $7.48 $1.48 Million - $2.22 Million	296,405 New	296,405 $1.62 Million
Q1 2021 May 17, 2021	SELL	$7.19 - $14.95 $333,781 - $694,023	-46,423 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.66 - $14.66 $309,177 - $680,561	46,423 New	46,423 $504,000
Q3 2020 Nov 16, 2020	SELL	$8.69 - $14.47 $212,540 - $353,907	-24,458 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.21 - $11.03 $127,426 - $269,771	24,458 New	24,458 $261,000
Q2 2018 Aug 14, 2018	SELL	$10.16 - $13.65 $133,096 - $178,815	-13,100 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.47 - $12.98 $124,057 - $170,038	13,100 New	13,100 $170,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.